Enzolytics Inc. (ENZC) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Plano, TX, United States. The current CEO is Steven Sharabura.
ENZC has IPO date of 2009-04-08, 1 full-time employees, listed on the Other OTC, a market capitalization of $1.18M.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
